For the quarter ending 2026-03-31, BCLI had -$70K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Increase (decrease) in trade payables | - | 647 | 423 | -83 |
| Net loss | -2,127 | -2,434 | -2,106 | -5,767 |
| Depreciation | 37 | 48 | 48 | 103 |
| Stock-based compensation related to options granted to employees and directors | 133 | 143 | 157 | 1,220 |
| Change in operating lease liability | 2 | 8 | 11 | 68 |
| Decrease (increase) in other accounts receivable and prepaid expenses | -109 | -224 | -188 | 495 |
| Increase in accrued expense | - | 85 | - | - |
| Increase in accounts payables | 250 | - | - | - |
| Gain on change in fair value of warrants (note 7) | - | 0 | 0 | -179 |
| Increase in interest expense | 82 | - | - | - |
| Proceeds from warrants issuance (note 7) | - | 0 | 0 | 1,501 |
| Increase (decrease) in other accounts payable and accrued expenses | - | - | 177 | - |
| Increase in employees related liability and accrued expenses | 194 | 716 | - | - |
| Debt-for-equity swap | - | 0 | 0 | -450 |
| Net cash used in operating activities | -1,320 | -740 | -1,102 | -5,133 |
| Proceeds from issuance of shares in at-the-market (atm) offering (note 8) | - | -1 | 313 | 4,035 |
| Proceeds from issuance of shares for private placement (note 4) | 970 | - | - | - |
| Proceeds from short-term loans (note 6) | 280 | 781 | 0 | -199 |
| Net cash provided by financing activities | 1,250 | 780 | 313 | 5,787 |
| Increase (decrease) in cash and cash equivalents | -70 | 40 | -789 | 654 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 276 | 236 | 371 | - |
| Cash, cash equivalents and restricted cash at end of the period | 206 | 276 | 236 | - |
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)